A 4-week Dose-Ranging, Dose-Interval, Efficacy, Safety and Tolerability Study of GSK961081 in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Inclusion Criteria: * Outpatient Subjects * Subjects who give their signed and dated informed consent to participate * 40 or more years of age, inclusive, at Visit 1 * Male or females * Subjects with an established clinical history of COPD * Current or previous cigarette smokers with a history of ≥ 10 pack-years of cigarette smoking * Subjects with the following liver function test values: * Subjects with a measured post-salbutamol FEV1/FVC ratio of \< 0.70 at Visit 1 (Screening). * Subjects with a measured post-salbutamol FEV1 30-70% of predicted normal values Exclusion Criteria: * Women who are pregnant or lactating or are planning to become pregnant during the study. * Current diagnosis of asthma * Other significant respiratory disorders besides COPD, including alpha-1 deficiency * Previous lung resection surgery * Significant abnormalities in chest x-ray presentation * Hospitalization for a COPD exacerbation within 12 weeks prior screening * Use of oral corticosteroids or antibiotics for COPD or antibiotics for a lower respiratory tract infection within 6 weeks * Any significant disease that would put subject at risk through study participation * BMI greater than 35 * Pacemaker * Significantly abnormal ECG, clinical lab finding (including Hepatitis B or C) * Cancer * Allergy or hypersensitivity to beta adrenergic receptor-agonist, sympathomimetic, anticholinergic/anti-muscarinic receptor antagonist, or inhaler excipients * Diseases that would contra-indicate the use of anticholinergics * Use of sysemic corticosteroids within 6 weeks of screening * Use of long-acting beta-agonists within 48 hours of screening * Use of tiotropium within 7 days of screening * Use of theophyllines or anti-leukotrienes within 48 hours of screening * Use of short-acting bronchodilators within 4 hours of screening * Use of investigational medicines within 30 days of screening * Use of high dose inhaled corticosteroids * Use of long-term oxygen therapy, CPAP or NIPPV * Participation in the acute phase of a pulmonary rehabilitation program within 4 weeks prior to Visit 1 * Regular (q.i.d or greater) use of short acting bronchodilators, including nebulized therapy * Affiliation with Investigator Site * Questionable Validity of Consent * Previous use of GSK961081